Morgan Stanley Gives Astrazeneca (LON:AZN) Shareholders a Gift With Today’s Upgrade


Astrazeneca (LON:AZN) Stock Upgrade

Morgan Stanley boosted the rating on Astrazeneca (LON:AZN) shares to a Overweight. This change in their rating was just issued to clients and investors in a recent research report earlier today.

From a total of 29 analysts covering AstraZeneca PLC (LON:AZN) stock, 18 rate it a ”Buy”, 6 a “Sell”, and 10 a ”Hold”. This means that 53% of the ratings are positive. The highest target price is GBX 94.72 while the lowest target price is GBX 36. The mean of all analyst targets is GBX 70.29 with a 6.68% above today’s (GBX 4528.65) stock price. AstraZeneca PLC was the topic of 116 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Bernstein maintained shares on December 1 with “Market Perform” rating. Helvea maintained shares with “Hold” rating and GBX 4400 target share price in a report from a November 23. UBS maintained AZN stock in a recent report from November 25 with “Buy” rating. Jefferies maintained the rating on November 18. Jefferies has a “Buy” rating and a GBX 5600 price target on shares. Finally, Credit Suisse maintained the stock with “Underperform” rating in a report issued on a November 24.

The stock increased 0.58% or GBX 26.15 on December 1, striking GBX 4528.65. Approximately 1.90M shares of stock traded hands. AstraZeneca plc (LON:AZN) has risen 0.92% since May 4, 2015 and is uptrending. It has outperformed by 2.54% the S&P500.

 Morgan Stanley Gives Astrazeneca (LON:AZN) Shareholders a Gift With Today’s Upgrade

AstraZeneca PLC is a global biopharmaceutical company. The company has a market cap of 57.09 billion GBP. The Firm discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. It has 51.03 P/E ratio. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.” Get a free copy of the Zacks research report on AstraZeneca plc (AZN)